The Lancet Child & Adolescent Health, 3, 803-813
& Becker, C
24 Novo Nordisk overcame these barriers by formulating with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), which acts both as a buffering agent, protecting the peptide from acid degradation, and a permeation enhancer, to increase absorption
Although, the majority of papillary and follicular thyroid carcinomas are sporadic, the familial forms are rare and can be divided into two groups
In January of 2025, Ozempic was also approved to reduce the risk of kidney disease progression, kidney failure, and death from cardiovascular disease in individuals with chronic kidney disease and type 2 diabetes
Current UK regulatory position includes: Warnings and precautions regarding thyroid C-cell tumours based on animal data, with acknowledgement that human relevance is uncertain Advice regarding pancreatitis risk, with recommendations to discontinue if acute pancreatitis is suspected and not to restart if confirmed No restrictions based on general cancer risk, as human evidence does not support an increased overall malignancy risk Monitoring for gallbladder disease, which has been associated with GLP-1 receptor agonist use The Summary of Product Characteristics (SmPC) for each GLP-1 medicine includes detailed safety information that healthcare professionals should review before prescribing